- Boehringer acquires exclusive license for Sitryx's preclinical small molecule program.
- The program targets autoimmune and inflammatory diseases with novel oral therapies.
- Sitryx to receive over $500 million in potential payments and tiered royalties.
- Boehringer assumes responsibility for research, development, and commercialization.
License Agreement
Boehringer Ingelheim has secured an exclusive license from Sitryx Therapeutics for a preclinical small molecule program. This program aims to develop novel oral therapies for autoimmune and inflammatory diseases.
Program Potential
The licensed program offers a potentially disease-modifying treatment approach across multiple indications. It addresses the growing global burden of autoimmune and inflammatory diseases, where current therapies often fail to provide sustainable control.
Financial Terms
Sitryx will receive upfront and near-term payments, with potential development, regulatory, and commercialization milestone payments exceeding $500 million. Additionally, Sitryx is entitled to tiered royalties on future sales.
Responsibilities
Boehringer Ingelheim will take full responsibility for further research, clinical development, and commercialization of the program. This collaboration leverages Boehringer's global capabilities in immunology and drug development.
